Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kashiwagi, A.
Right arrow Articles by Shigeta, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kashiwagi, A.
Right arrow Articles by Shigeta, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 35, Issue 10 1085-1089, Copyright © 1986 by American Diabetes Association

ARTICLES

New alpha 2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients

A Kashiwagi, Y Harano, M Suzuki, H Kojima, M Harada, Y Nishio and Y Shigeta

Effects of oral administration of DG-5128, a new oral hypoglycemic agent, on glycemic control after a mixed meal and an in vivo glucose disposal were measured in subjects with nonobese non-insulin-dependent diabetes mellitus (NIDDM). Oral administration of DG-5128 significantly (P less than .05) enhanced insulin secretion both 30 and 60 min after a mixed meal (550 kcal), with a concomitant decrease in postprandial plasma glucose levels at 60 and 120 min. Glucose disposal rate between the 2nd and 4th h of a euglycemic insulin clamp, developed through a constant infusion of insulin (0.77 mU X kg-1 X min-1) together with somatostatin (80 ng X kg-1 X min-1), was 2.5-fold higher in a DG-5128-treated group (P less than .01) than in a control group. However, there was no difference between the two groups in either plasma glucose concentration or plasma insulin concentration at either the 2nd or the 4th h. These results indicate that DG-5128 is effective in controlling plasma glucose levels in subjects with NIDDM by stimulation of both insulin secretion and in vivo glucose disposal.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
T. Leon-Quinto, C. Magnan, and B. Portha
Altered Activity of the Autonomous Nervous System as a Determinant of the Impaired {beta}-Cell Secretory Response after Protein-Energy Restriction in the Rat
Endocrinology, August 1, 1998; 139(8): 3382 - 3389.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Hoy, K. Bokvist, W. Xiao-Gang, J. Hansen, K. Juhl, P.-O. Berggren, K. Buschard, and J. Gromada
Phentolamine Inhibits Exocytosis of Glucagon by Gi2 Protein-dependent Activation of Calcineurin in Rat Pancreatic alpha -Cells
J. Biol. Chem., January 5, 2001; 276(2): 924 - 930.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1986 by the American Diabetes Association.